ScreenerHero

AVBP ArriVent BioPharma, Inc.

NAS · US · Healthcare · Biotechnology · arrivent.com
16.89USD+11.93%Mkt Cap: 832.81M $P/E: —

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap832.81M USD
Enterprise Value371.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-166.31M USD
Revenue/Share—
Last Price16.89 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees77
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.84
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.99
EPS (TTM)-3.64
EPS (Forward)-3.93
52W Range
11.3723% of range35.83
52W High35.83 USD
52W Low11.37 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.13%
ROA-49.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-160.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-10.74%
Net Debt-372.77M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio14.16
Quick Ratio13.40
Book Value/Sh7.59 USD
Cash/Share7.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.70 USD
Upside (mean)+164.7%
Target Range40.00 USD – 50.00 USD
40.00+164.7% to mean50.00
# Analysts10
Ownership
Shares Out.49.31M
Float32.11M
Insiders1.54%
Institutions98.80%
Short Interest
Short Ratio18.9d
Short % Float18.86%
Short % Out.17.78%
Shares Short8.77M
Short (prev mo.)8.23M
Technical
SMA 5029.85 (-43.4%)
SMA 20027.35 (-38.2%)
Beta1.35
S&P 52W Chg16.45%
Avg Vol (30d)1.33M
Avg Vol (10d)696.06K
Technical Indicators
RSI (14)24.0
MACD-2.1570
MACD Signal-0.8567
MACD Hist.-1.3003
BB Upper36.28 USD
BB Middle27.94 USD
BB Lower19.61 USD
BB Width59.64%
ATR (14)2.631 USD
Vol Ratio (20d)2.69x